1. Home
  2. AVX vs LUNG Comparison

AVX vs LUNG Comparison

Compare AVX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AVX

Avax One Technology Ltd.

N/A

Current Price

$0.52

Market Cap

50.6M

Sector

Industrials

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.28

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVX
LUNG
Founded
2017
1995
Country
Canada
United States
Employees
7
N/A
Industry
Metal Fabrications
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AVX
LUNG
Price
$0.52
$1.28
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
604.7K
496.8K
Earning Date
05-15-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.44
$1.13
52 Week High
$2.27
$3.88

Technical Indicators

Market Signals
Indicator
AVX
LUNG
Relative Strength Index (RSI) 45.10 45.18
Support Level $0.46 $1.27
Resistance Level $0.60 $1.45
Average True Range (ATR) 0.04 0.09
MACD 0.01 0.00
Stochastic Oscillator 53.72 37.04

Price Performance

Historical Comparison
AVX
LUNG

About AVX Avax One Technology Ltd.

AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. It focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: